These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 30615313)

  • 1. [Myeloma mouse models].
    Nihon Rinsho; 2016 Jul; 74 Suppl 5():92-5. PubMed ID: 30615313
    [No Abstract]   [Full Text] [Related]  

  • 2. [Experimental animal models of multiple myeloma].
    Miyakawa Y
    Nihon Rinsho; 2007 Dec; 65(12):2211-7. PubMed ID: 18069262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Establishment of multiple myeloma mouse models expressing brain derived neurotrophic factor].
    Wang YD; Hu Y; Zhang L; Huang J; Sun CY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Oct; 15(5):967-72. PubMed ID: 17956671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mouse models of human myeloma.
    Mitsiades CS; Anderson KC; Carrasco DR
    Hematol Oncol Clin North Am; 2007 Dec; 21(6):1051-69, viii. PubMed ID: 17996588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of current murine models of multiple myeloma used to assess the efficacy of therapeutic agents on tumour growth and bone disease.
    Paton-Hough J; Chantry AD; Lawson MA
    Bone; 2015 Aug; 77():57-68. PubMed ID: 25868800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Transforming Growth Factor-β Activation Diminishes Tumor Progression and Osteolytic Bone Disease in Mouse Models of Multiple Myeloma.
    Lu A; Pallero MA; Lei W; Hong H; Yang Y; Suto MJ; Murphy-Ullrich JE
    Am J Pathol; 2016 Mar; 186(3):678-90. PubMed ID: 26801735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma.
    Murillo O; Arina A; Hervas-Stubbs S; Gupta A; McCluskey B; Dubrot J; Palazón A; Azpilikueta A; Ochoa MC; Alfaro C; Solano S; Pérez-Gracia JL; Oyajobi BO; Melero I
    Clin Cancer Res; 2008 Nov; 14(21):6895-906. PubMed ID: 18980984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PEGylated long-circulating liposomes deliver homoharringtonine to suppress multiple myeloma cancer stem cells.
    Li M; Shi F; Fei X; Wu S; Wu D; Pan M; Luo S; Gu N; Dou J
    Exp Biol Med (Maywood); 2017 May; 242(9):996-1004. PubMed ID: 28056549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mouse models and the RANKL/OPG axis in myeloma bone disease.
    Dingli D; Russell SJ
    Leukemia; 2007 Oct; 21(10):2090-3. PubMed ID: 17878922
    [No Abstract]   [Full Text] [Related]  

  • 10. Severe combined immunodeficiency (SCID) mouse modeling of P-glycoprotein chemosensitization in multidrug-resistant human myeloma xenografts.
    Bellamy WT; Odeleye A; Huizenga E; Dalton WS; Weinstein RS; Grogan TM
    Clin Cancer Res; 1995 Dec; 1(12):1563-70. PubMed ID: 9815957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple myeloma and related disorders. Lessons from an animal model.
    Radl J
    Pathol Biol (Paris); 1999 Feb; 47(2):109-14. PubMed ID: 10192877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adoptive B-cell transfer mouse model of human myeloma.
    Tompkins VS; Rosean TR; Holman CJ; DeHoedt C; Olivier AK; Duncan KM; Jing X; Foor SD; Acevedo MR; Walsh SA; Tricot G; Zhan F; Janz S
    Leukemia; 2016 Apr; 30(4):962-6. PubMed ID: 26202932
    [No Abstract]   [Full Text] [Related]  

  • 13. A mouse model for immunotherapy of myeloma.
    Bogen B
    Hematol J; 2002; 3(5):224-9. PubMed ID: 12391539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitochondrial genome of a spontaneous multiple myeloma bone cancer model mouse C57BL/KaLwRij strain.
    Liu ZG; Tang B; Zeng Y; He N; Wang ZY; Han H; Wang L; Wang TZ; Yu HL; Xiong M
    Mitochondrial DNA A DNA Mapp Seq Anal; 2016 Nov; 27(6):4071-4072. PubMed ID: 25693717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The SCID-hu myeloma model.
    Epstein J; Yaccoby S
    Methods Mol Med; 2005; 113():183-90. PubMed ID: 15968103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Animal model of human disease. Multiple myeloma.
    Radl J; Croese JW; Zurcher C; Van den Enden-Vieveen MH; de Leeuw AM
    Am J Pathol; 1988 Sep; 132(3):593-7. PubMed ID: 3414786
    [No Abstract]   [Full Text] [Related]  

  • 17. Pleurocidin-family cationic antimicrobial peptides mediate lysis of multiple myeloma cells and impair the growth of multiple myeloma xenografts.
    Hilchie AL; Conrad DM; Coombs MR; Zemlak T; Doucette CD; Liwski RS; Hoskin DW
    Leuk Lymphoma; 2013 Oct; 54(10):2255-62. PubMed ID: 23350892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NOD/SCID-GAMMA mice are an ideal strain to assess the efficacy of therapeutic agents used in the treatment of myeloma bone disease.
    Lawson MA; Paton-Hough JM; Evans HR; Walker RE; Harris W; Ratnabalan D; Snowden JA; Chantry AD
    PLoS One; 2015; 10(3):e0119546. PubMed ID: 25768011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib has potent antitumor activity against multiple myeloma in vitro, ex vivo, and in vivo in the 5T33MM mouse model.
    Kharaziha P; De Raeve H; Fristedt C; Li Q; Gruber A; Johnsson P; Kokaraki G; Panzar M; Laane E; Osterborg A; Zhivotovsky B; Jernberg-Wiklund H; Grandér D; Celsing F; Björkholm M; Vanderkerken K; Panaretakis T
    Cancer Res; 2012 Oct; 72(20):5348-62. PubMed ID: 22952216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma.
    Vanderkerken K; Medicherla S; Coulton L; De Raeve H; Willems A; Lawson M; Van Camp B; Protter AA; Higgins LS; Menu E; Croucher PI
    Cancer Res; 2007 May; 67(10):4572-7. PubMed ID: 17495322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.